Impel NeuroPharma has announced that 3M New Ventures (3M NV) led the investment in its $12 million Series B financing round to raise money for commercialization of Impel’s Precision Olfactory Delivery (POD) platform. Impel recently announced a partnership with 3M Drug Delivery Systems for development and commercialization of the intranasal technology.
Impel CEO Michael Hite said, “We are excited to have 3M NV participate in our Series B round. We look forward to accelerating the commercialization of the POD technology and continuing our clinical stage development programs in Alzheimer’s Disease, migraine, and pain management.”
Read the Impel NeuroPharma press release.
